Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.

Publication/Presentation Date

2-21-2021

Abstract

Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.

Volume

146

Issue

4

First Page

1157

Last Page

1162

ISSN

1364-5528

Disciplines

Medicine and Health Sciences

PubMedID

33426547

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article

Share

COinS